Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya
Authors & affiliation
Kim Steegen, Stanley Lüchters, Kenny Dauwe, Jacqueline Reynaerts, Kishor Mandaliya, Walter Jaoko, Jean Plum, Marleen Temmerman, Chris Verhofstede
Abstract
Access to antiretroviral therapy (ART) is increasing in resource-limited settings (RLS) and can successfully reduce HIV-related morbidity and mortality. However, virologic failure and development of viral drug resistance can result in reduced treatment options and disease progression. Additionally, transmission of resistant virus, and particularly multi-drug resistance, could become a public health concern. This study evaluated treatment success and development of ART drug resistance after short-term treatment among patients attending the Comprehensive HIV Care Centre (CCC) of Coast Province General Hospital, Mombasa, Kenya. One hundred and fifty HIV-infected individuals receiving ART were consecutively recruited to participate in the study. After determination of plasma viral load, patients with detectable viral load levels were subjected to genotypic drug resistance testing. At the time of sampling, 132 of the 150 participants were on ART for more than 6 months (median 21 months, IQR = 12-26). An efficient viral load reduction to below 50 copies/ml was observed in 113 (85.6%) of them. Of the 19 patients with a detectable viral load, sequencing of the protease (PR) and reverse transcriptase (RT) gene was successful in 16. Eleven (11) of these 16 patients were infected with a subtype A1 virus. Major PR mutations were absent, but mutations associated with drug resistance in RT were detected in 14 of the 16 patients (87.5%). High-level resistance against at least 2 drugs of the ART regimen was observed in 9/14 (64.3%). The 3TC mutation M184V and the NNRTI mutation K103N were most frequent but also the multi-drug resistance Q151M and the broad NRTI cross-resistance K65R were observed. The results of this study revealed a high rate of treatment success after short term ART in patients treated at a public provincial hospital in a RLS. Nevertheless, the observed high risk of accumulation of resistance mutations among patients failing treatment and the selection of multi-drug resistance mutations in some, remains of great concern for future treatment options and potential transmission to partners.
Publication date:
2009
Staff members:
Stanley Luchters
Marleen Temmerman
Link to publication
Attachments
1742-6405-6-12.pdf (open)Related publications
Olivier Degomme, Emilie Peeters, Hedwig Deconinck, Alban Ylli, Albana Fico, Gentiana Qirjako, Dorina Ttocaj, Sara De Meyer, Kristien Michielsen, Anna Page, Wina Baeha, Kristi Praptiwi, Miranda van Reeuwijk, Beatriz Manuel, Elin C. Larsson, Carmen Ortiz, Bernardo Vega, Monserrath Jerves, Simukai Shamu, Annemiek Seeuws, Anna Galle, Anne Nobels, Ines Keygnaert, Hazel Barrett, Nina Van Eekert, Tammary Esho, Els Leye, Carles Pericas Escale, Samuel Thuo Kimani, Sofie Thielemans, Dara De Schutter, Remi Moerkerke, Louis De Backer, Viola N. Nyakato, Elizabeth Kemigisha, Wei Hong Zhang, Marleen Temmerman, Lina Hu, Shangchun Wu, Kaiyan Pei, Charlotte Neves de Oliveira, Argyro Chatzinikolaou, Eva Lievens
2022 Barriers and facilitators to cervical cancer screening among under- and neverscreened women in Belgium : a qualitative study on community and healthcare providers’ perspectiveBo Verberckmoes, Elien De Paepe, Janne De Vestele, Heleen Vermandere, Ines Keygnaert, Olivier Degomme
2022 Inhoudelijk eindrapport Opleiding seksueel geweld voor de Family Justice Centers & Ketenaanpak Intrafamiliaal GeweldSaar Baert, Lisa Fomenko, Nele Vaerewijck, Lotte De Schrijver, An-Sofie Van Parys, Ines Keygnaert